{"transactions":[{"id":779325,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":47354,"kind":"person","name":"KEYSER D JEFFREY","position":1,"cik":"0001393516","reported_name":"KEYSER D JEFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock purchase warrant (Right to Buy)","published_at":"2026-05-14T20:10:08.000Z","date":"2026-05-12","kind":"purchase","planned":false,"acquired":false,"shares":48544,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities were acquired in the issuer's offering of securities that closed on May 14, 2026. The warrants are exercisable commencing on November 14, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reported securities were acquired in the issuer's offering of securities that closed on May 14, 2026. The warrants are exercisable commencing on November 14, 2026."}],"balance_after":48544,"derivative":{"exercise_price":2.27,"expiration_date":"2031-11-13","underlying":"Common Stock","underlying_shares":48544},"source":{"system":"sec-edgar","filing":"0001493152-26-023082","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315226023082/ownership.xml","form_type":"4"}},{"id":779324,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":47354,"kind":"person","name":"KEYSER D JEFFREY","position":1,"cik":"0001393516","reported_name":"KEYSER D JEFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock, $0.001 par value","published_at":"2026-05-14T20:10:08.000Z","date":"2026-05-12","kind":"purchase","planned":false,"acquired":true,"shares":48544,"price":2.06,"value":100000.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities were acquired in the issuer's offering of securities that closed on May 14, 2026. The warrants are exercisable commencing on November 14, 2026."}],"balance_after":94303,"source":{"system":"sec-edgar","filing":"0001493152-26-023082","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315226023082/ownership.xml","form_type":"4"}},{"id":940100,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":47354,"kind":"person","name":"KEYSER D JEFFREY","position":1,"cik":"0001393516","reported_name":"KEYSER D JEFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-13T21:05:14.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":28844,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 12-month period commencing February 9, 2026."}],"balance_after":28844,"derivative":{"exercise_price":3.49,"expiration_date":"2036-01-08","underlying":"Common Stock","underlying_shares":28844},"source":{"system":"sec-edgar","filing":"0001493152-26-002024","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315226002024/ownership.xml","form_type":"4"}},{"id":940099,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":47354,"kind":"person","name":"KEYSER D JEFFREY","position":1,"cik":"0001393516","reported_name":"KEYSER D JEFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-13T21:05:14.000Z","date":"2026-01-09","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing February 9, 2026."}],"balance_after":25000,"derivative":{"exercise_price":3.49,"expiration_date":"2036-01-08","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001493152-26-002024","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315226002024/ownership.xml","form_type":"4"}},{"id":1033790,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":47354,"kind":"person","name":"KEYSER D JEFFREY","position":1,"cik":"0001393516","reported_name":"KEYSER D JEFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-23T20:05:13.000Z","date":"2021-11-04","kind":"grant","planned":false,"acquired":true,"shares":3200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on November 4, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing December 4, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on November 4, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing December 4, 2021."}],"balance_after":3200,"derivative":{"exercise_price":5.04,"expiration_date":"2031-11-03","underlying":"Common Stock","underlying_shares":3200},"source":{"system":"sec-edgar","filing":"0001493152-25-014614","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315225014614/ownership.xml","form_type":"4"}},{"id":1033789,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":47354,"kind":"person","name":"KEYSER D JEFFREY","position":1,"cik":"0001393516","reported_name":"KEYSER D JEFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-23T20:05:13.000Z","date":"2021-11-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on November 4, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing December 4, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on November 4, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing December 4, 2021."}],"balance_after":0,"derivative":{"exercise_price":10.32,"expiration_date":"2031-11-03","underlying":"Common Stock","underlying_shares":3200},"source":{"system":"sec-edgar","filing":"0001493152-25-014614","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315225014614/ownership.xml","form_type":"4"}},{"id":1033788,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":47354,"kind":"person","name":"KEYSER D JEFFREY","position":1,"cik":"0001393516","reported_name":"KEYSER D JEFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-23T20:05:13.000Z","date":"2020-06-15","kind":"grant","planned":false,"acquired":true,"shares":9135,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and provides for vesting in equal monthly increments over a 36-month period commencing July 15, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and provides for vesting in equal monthly increments over a 36-month period commencing July 15, 2020."}],"balance_after":9135,"derivative":{"exercise_price":5.04,"expiration_date":"2030-06-14","underlying":"Common Stock","underlying_shares":9135},"source":{"system":"sec-edgar","filing":"0001493152-25-014614","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315225014614/ownership.xml","form_type":"4"}},{"id":1033787,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":47354,"kind":"person","name":"KEYSER D JEFFREY","position":1,"cik":"0001393516","reported_name":"KEYSER D JEFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-23T20:05:13.000Z","date":"2020-06-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9135,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and provides for vesting in equal monthly increments over a 36-month period commencing July 15, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the \"old\" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and provides for vesting in equal monthly increments over a 36-month period commencing July 15, 2020."}],"balance_after":0,"derivative":{"exercise_price":15,"expiration_date":"2030-06-14","underlying":"Common Stock","underlying_shares":9135},"source":{"system":"sec-edgar","filing":"0001493152-25-014614","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315225014614/ownership.xml","form_type":"4"}},{"id":1448091,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":47354,"kind":"person","name":"KEYSER D JEFFREY","position":1,"cik":"0001393516","reported_name":"KEYSER D JEFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Warrants","published_at":"2024-07-26T20:15:16.000Z","date":"2024-07-24","kind":"other","planned":false,"acquired":false,"shares":3832,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 24, 2024, the Reporting Person exercised a Series A Warrant to purchase 3,832 shares of common stock at an exercise price of $3.13 per share."}],"balance_after":0,"derivative":{"exercise_price":3.13,"exercise_date":"2019-07-25","expiration_date":"2024-07-25","underlying":"Common Stock","underlying_shares":3832},"source":{"system":"sec-edgar","filing":"0001493152-24-029238","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315224029238/ownership.xml","form_type":"4"}},{"id":1448090,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":47354,"kind":"person","name":"KEYSER D JEFFREY","position":1,"cik":"0001393516","reported_name":"KEYSER D JEFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-07-26T20:15:16.000Z","date":"2024-07-24","kind":"other","planned":false,"acquired":true,"shares":3832,"price":3.13,"value":11994.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 24, 2024, the Reporting Person exercised a Series A Warrant to purchase 3,832 shares of common stock at an exercise price of $3.13 per share."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001493152-24-029238","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315224029238/ownership.xml","form_type":"4"}},{"id":1452647,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":47354,"kind":"person","name":"KEYSER D JEFFREY","position":1,"cik":"0001393516","reported_name":"KEYSER D JEFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-17T20:30:16.000Z","date":"2024-07-15","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 36-month period commencing August 15, 2024."}],"balance_after":5000,"derivative":{"exercise_price":4.35,"expiration_date":"2034-07-15","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001493152-24-028184","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315224028184/ownership.xml","form_type":"4"}},{"id":2521510,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":47354,"kind":"person","name":"KEYSER D JEFFREY","position":1,"cik":"0001393516","reported_name":"KEYSER D JEFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-08T21:05:21.000Z","date":"2021-11-04","kind":"grant","acquired":true,"shares":3200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 36-month period commencing upon December 4, 2021."}],"balance_after":3200,"derivative":{"exercise_price":10.32,"expiration_date":"2031-11-04","underlying":"Common Stock","underlying_shares":3200},"source":{"system":"sec-edgar","filing":"0001213900-21-057325","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763950/000121390021057325/ownership.xml","form_type":"4"}},{"id":3110720,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":47354,"kind":"person","name":"KEYSER D JEFFREY","position":1,"cik":"0001393516","reported_name":"KEYSER D JEFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2020-06-15T21:16:19.000Z","date":"2020-06-15","kind":"grant","acquired":true,"shares":9135,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Reporting Person was granted options to purchase 9,135 shares of the Issuer's common stock at the exercise price equal to the price per share sold in the Issuer's IPO. The options granted will vest in equal monthly increments over a 36 month period commencing upon the closing of the Issuer's IPO, which is the grant date of the options. Under the Amended and Restated 2018 Equity Incentive Plan, the options may not be exercised after the tenth anniversary of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Reporting Person was granted options to purchase 9,135 shares of the Issuer's common stock at the exercise price equal to the price per share sold in the Issuer's IPO. The options granted will vest in equal monthly increments over a 36 month period commencing upon the closing of the Issuer's IPO, which is the grant date of the options. Under the Amended and Restated 2018 Equity Incentive Plan, the options may not be exercised after the tenth anniversary of the grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Reporting Person was granted options to purchase 9,135 shares of the Issuer's common stock at the exercise price equal to the price per share sold in the Issuer's IPO. The options granted will vest in equal monthly increments over a 36 month period commencing upon the closing of the Issuer's IPO, which is the grant date of the options. Under the Amended and Restated 2018 Equity Incentive Plan, the options may not be exercised after the tenth anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Reporting Person was granted options to purchase 9,135 shares of the Issuer's common stock at the exercise price equal to the price per share sold in the Issuer's IPO. The options granted will vest in equal monthly increments over a 36 month period commencing upon the closing of the Issuer's IPO, which is the grant date of the options. Under the Amended and Restated 2018 Equity Incentive Plan, the options may not be exercised after the tenth anniversary of the grant date."}],"balance_after":9135,"derivative":{"exercise_price":15,"underlying":"Common Stock","underlying_shares":9135},"source":{"system":"sec-edgar","filing":"0001213900-20-015034","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1763950/000121390020015034/ownership.xml","form_type":"4"}},{"id":3110719,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":47354,"kind":"person","name":"KEYSER D JEFFREY","position":1,"cik":"0001393516","reported_name":"KEYSER D JEFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-06-15T21:16:19.000Z","date":"2020-06-15","kind":"exercise","acquired":false,"shares":18349,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"In connection with the IPO, the 18,349 shares of Series A Preferred Stock held by the Reporting Person were automatically converted for no additional consideration into 31,927 shares of common stock immediately prior to the closing of the Issuer's IPO."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the IPO, the 18,349 shares of Series A Preferred Stock held by the Reporting Person were automatically converted for no additional consideration into 31,927 shares of common stock immediately prior to the closing of the Issuer's IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the IPO, the 18,349 shares of Series A Preferred Stock held by the Reporting Person were automatically converted for no additional consideration into 31,927 shares of common stock immediately prior to the closing of the Issuer's IPO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"In connection with the IPO, the 18,349 shares of Series A Preferred Stock held by the Reporting Person were automatically converted for no additional consideration into 31,927 shares of common stock immediately prior to the closing of the Issuer's IPO."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"In connection with the Issuer's initial public offering (\"IPO\"), the Issuer effected a 1.74-for-1 stock split on its outstanding common stock, which became effective immediately prior to the closing of the Issuer's IPO (\"Stock Split\"). The share amounts reflect the Stock Split."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"In connection with the IPO, the 18,349 shares of Series A Preferred Stock held by the Reporting Person were automatically converted for no additional consideration into 31,927 shares of common stock immediately prior to the closing of the Issuer's IPO."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":31927},"source":{"system":"sec-edgar","filing":"0001213900-20-015034","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1763950/000121390020015034/ownership.xml","form_type":"4"}},{"id":3110718,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":47354,"kind":"person","name":"KEYSER D JEFFREY","position":1,"cik":"0001393516","reported_name":"KEYSER D JEFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-15T21:16:19.000Z","date":"2020-06-15","kind":"exercise","acquired":true,"shares":31927,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"In connection with the Issuer's initial public offering (\"IPO\"), the Issuer effected a 1.74-for-1 stock split on its outstanding common stock, which became effective immediately prior to the closing of the Issuer's IPO (\"Stock Split\"). The share amounts reflect the Stock Split."},{"field":"shares","element":"transactionShares","label":"F2","text":"In connection with the IPO, the 18,349 shares of Series A Preferred Stock held by the Reporting Person were automatically converted for no additional consideration into 31,927 shares of common stock immediately prior to the closing of the Issuer's IPO."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the IPO, the 18,349 shares of Series A Preferred Stock held by the Reporting Person were automatically converted for no additional consideration into 31,927 shares of common stock immediately prior to the closing of the Issuer's IPO."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"In connection with the Issuer's initial public offering (\"IPO\"), the Issuer effected a 1.74-for-1 stock split on its outstanding common stock, which became effective immediately prior to the closing of the Issuer's IPO (\"Stock Split\"). The share amounts reflect the Stock Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In connection with the IPO, the 18,349 shares of Series A Preferred Stock held by the Reporting Person were automatically converted for no additional consideration into 31,927 shares of common stock immediately prior to the closing of the Issuer's IPO."}],"balance_after":41927,"source":{"system":"sec-edgar","filing":"0001213900-20-015034","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763950/000121390020015034/ownership.xml","form_type":"4"}},{"id":3110717,"issuer":{"id":7525,"kind":"organization","name":"Lantern Pharma Inc."},"owners":[{"id":47354,"kind":"person","name":"KEYSER D JEFFREY","position":1,"cik":"0001393516","reported_name":"KEYSER D JEFFREY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-15T21:14:03.000Z","date":"2020-06-11","kind":"purchase","acquired":true,"shares":10000,"price":15,"value":150000.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The 10,000 shares of common stock were purchased by the Reporting Person at the offering price $15.00 per share for a total purchase price of $150,000, in connection with Issuer's initial public offering which closed on June 15, 2020. The Reporting Person received notification of the order on June 11, 2020."},{"field":"shares","element":"transactionShares","label":"F1","text":"The 10,000 shares of common stock were purchased by the Reporting Person at the offering price $15.00 per share for a total purchase price of $150,000, in connection with Issuer's initial public offering which closed on June 15, 2020. The Reporting Person received notification of the order on June 11, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The 10,000 shares of common stock were purchased by the Reporting Person at the offering price $15.00 per share for a total purchase price of $150,000, in connection with Issuer's initial public offering which closed on June 15, 2020. The Reporting Person received notification of the order on June 11, 2020."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001213900-20-015029","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763950/000121390020015029/ownership.xml","form_type":"4"}}]}